NeuroPace, Inc. Investigation - NPCE

Company
NeuroPace, Inc. (NASDAQ: NPCE)

Learn more about the NeuroPace, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

NeuroPace, Inc. Investigation Details

NeuroPace, Inc. shares fell more than 37% after the Company reported third quarter revenue of $23.1 million-roughly 15% below consensus estimates of approximately $27.1 to $27.2 million-and a $3.3 million GAAP net loss, with total revenue declining 1.1% year over year. Concurrently, the Company reduced its full-year 2026 revenue guidance to $91 to $92 million from its prior range of $99.5 to $101.5 million. Management attributed the shortfall to sales-force restructuring, disruptions at several large customer accounts, and the lingering impact of exiting the SEEG distribution business. Just weeks earlier, during an August 11, 2026 earnings call, Chief Financial Officer Patrick Williams stated that the Company was "increasing full-year total revenue guidance to a range of $99.5 million to $101.5 million" and expected third quarter RNS growth to be "approximately 20% year-over-year." On the same call, Chief Executive Officer Joel Becker cited "continued momentum in the core RNS business and disciplined execution across the organization" and highlighted indicators of the "breadth and durability of adoption across the business." The investigation concerns whether NeuroPace, Inc. adequately disclosed the sales-force restructuring and account-level customer disruptions ahead of its third quarter financial reset.

Get Started